OR1L4

Across TCGA pan-cancer cohorts, OR1L4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR1L4 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher OR1L4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR1L4 expression acts as an unfavorable survival marker.

HNSC, BRCA, and OV are the cancer types where OR1L4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.177	0.744	<.001	45	view →
BRCA	DFS	Median	All	0.510	0.950	<.001	34	view →
OV	DFS	Median	II,III,IV	0.195	0.541	.015	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	OS	Median	II,III,IV	0.176	0.677	.047	3	view →
SKCM	DFS	Median	III,IV	0.169	0.653	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR1L4–HNSC (OS)

Open the HNSC breakdown →